Suppression of RAD51 sensitizes cancer cells to DNA-damaging drugs [10, 22-25], and RAD51 overexpression contributes to chemotherapy resistance in several types of cancer including breast, prostate and human soft tissue sarcoma cells [10, 26-31]. Here, RAD51 is linked to cancer.